Federated Hermes

Federated Hermes’s X4 Pharmaceuticals XFOR Stock Holding History

Federated Hermes’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-149	Closed	-$283	–	2252
2025 Q2	$283	Buy	+149	New	+$610	﹤0.01%	2042
2022 Q2	–	Sell	-5	Closed	-$1K	–	2299
2022 Q1	$1K	Buy	+5	New	+$287	﹤0.01%	2129
2020 Q4	–	Sell	-2	Closed	-$1K	–	2346
2020 Q3	$1K	Sell	2 -2	-50%	-$479	﹤0.01%	2202
2020 Q2	$1K	Buy	+4	New	+$1.09K	﹤0.01%	2181
2020 Q1	–	Hold	0	–	-$1K	–	2365
2019 Q4	–	Hold	0	–	–	–	2152
2019 Q2	–	Sell	-2,286	Closed	-$1.19M	–	2231
2019 Q1	$1.19M	Hold	2,286	–	–	﹤0.01%	1246
2018 Q4	$954K	Buy	+2,286	New	+$872K	﹤0.01%	1301

Other funds holding XFOR

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $244M AUM 80.12% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return

Kingdon Capital Management New York $597M AUM 51.11% 1-Year Est. Return

Stempoint Capital New York $520M AUM 281.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return